Curanex Pharmaceuticals Inc
CURX
$0.60
-$0.01-1.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.54% | 71.45% | 403.15% | 102,000.00% | 1,239.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.54% | 71.45% | 403.15% | 102,000.00% | 1,239.39% |
| Operating Income | -30.54% | -71.45% | -403.15% | -102,000.00% | -1,239.39% |
| Income Before Tax | -36.43% | -71.57% | -980.31% | -- | -1,239.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.43% | -71.57% | -980.31% | -- | -1,239.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.43% | -71.57% | -980.31% | -- | -1,239.39% |
| EBIT | -30.54% | -71.45% | -403.15% | -102,000.00% | -1,239.39% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 86.41% | 95.74% | 72.99% | -- | -234.55% |
| Normalized Basic EPS | 86.09% | 95.69% | 87.88% | -- | -238.24% |
| EPS Diluted | 86.41% | 95.74% | 72.99% | -- | -234.55% |
| Normalized Diluted EPS | 86.09% | 95.69% | 87.88% | -- | -238.24% |
| Average Basic Shares Outstanding | 900.00% | 3,900.00% | 3,913.07% | 3,926.28% | 300.00% |
| Average Diluted Shares Outstanding | 900.00% | 3,900.00% | 3,913.07% | 3,926.28% | 300.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |